Healthcare Technology Report September 22, 2023
In a strategic move aimed at navigating recent challenges, Illumina, a leading genetic testing company, has announced the appointment of Jacob Thaysen as its new CEO. Thaysen, formerly of Agilent Technologies, brings a wealth of experience in the medical tools industry, particularly in the analytical instruments division. His tenure is set to commence on September 25, 2023.
Thaysen’s selection is seen as a calculated move by Illumina, especially in the wake of a turbulent period involving a proxy battle with billionaire investor Carl Icahn. Icahn’s disagreement with Illumina’s decision to repurchase cancer test manufacturer Grail in 2021, in spite of opposition from U.S. and European antitrust regulators, sparked the conflict. Icahn argued that Grail’s acquisition had incurred substantial costs for...
Today's Sponsors
Today's Sponsor